Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Icon Cancer Centre Mount Alvernia
National Cancer Centre
National University Hospital
Trial Status: Not Yet Recruiting
Ongoing, Recruiting
Principal Investigator(s):
Dr Hsieh Wen-son
Dr Amit Jain
Dr Ross Soo
Published by HT Digital Content Services with permission from Health Daily Digest....